

Creative Biolabs Boosts Offerings with Enhanced Non-IgG Antibody Engineering Service and More

Creative Biolabs, a leading provider of antibody services, has announced updates to three of its offerings: non-IgG therapeutic antibody engineering, autoantibody profiling, and ribosomal marker antibody development.

New York City, New York Mar 24, 2023 ([Issuewire.com](https://www.issuewire.com)) - Antibody development research has long been an exciting and rapidly advancing field with great promise for improving human health. And the advance of antibody engineering technology is expected to drive significant advances in the development of innovative therapies and cures. As one of the first-class biotech manufacturers, Creative Biolabs has taken a deep dive into the technology innovation and announced updates to three of its offerings: non-IgG therapeutic antibody engineering, autoantibody profiling, and ribosomal marker antibody development.

- [Non-IgG Therapeutic Antibody Engineering Service](#)

With a team of scientists focusing on unveiling more potential of non-IgG antibodies, including IgA, IgM, and IgE, the antibody engineering service has recruited an extensive range of strategies, which can be flexibly assembled to serve specific applications and purposes.

The expert team will help evaluate the existing project or design a custom one based on the technology platform covering chimeric non-IgG antibody, humanized non-IgG antibody, glycosylated non-IgG antibody, bi-specific non-IgG antibody, half-life extension, antibody isotype switching, and non-IgG antibody drug conjugation.

- [Natural Autoantibody Profiling Service](#)

The natural autoantibody profiling service has been updated to serve clients with autoantigen microarray and autoantibody microarray, with enhanced efficiency and reproducibility for clients' research on the identification of biomarkers and the prediction and diagnosis of diseases.

The autoantibody microarray is one of the hottest services, which has proved its capability based on the previous cases on cIgG, IgM, IgA and IgE autoantibodies from serum or other body fluids. While the newly updated autoantigen microarray features high throughput, load, and sensitivity, with each slide processing up to 15 samples (little samples are required with only 10ul needed).

- [Ribosomal Marker Antibody Development Service](#)

With complete hardware equipment, analysis tools, and data analysis charters, the professional bioinformatics analysis technical team introduces ribosomal marker antibody development service for the study of ribosome dynamics and morphology.

"Currently, antibody drugs have grown to be the dominant products in the biopharmaceutical market for the treatment of many diseases. To fully serve pharmaceutical companies' demand for high quality antibody products and services, we keep updating our offering to go wide and deep, hoping to help our clients make informed decisions and setting the right groundwork to succeed," said a scientist working at Creative Biolabs.

Creative Biolabs' efficient, cost-effective solutions will usher clients' projects to move at the speed of oncology with an integrated approach to development.

About Creative Biolabs

Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents, including the Phage Display Platform, Membrane Protein Platform, Hyperdoma™ Platform, and B-Cell Sorting Platform. The unmatched range of one-stop antibody development services covers the whole workflow from antibody discovery and engineering to bio-manufacturing.

Media Contact

Creative Biolabs

marketing@creative-biolabs.com

Source : Creative Biolabs

[See on IssueWire](#)